MedTrace Logo

1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement

NCT02756650 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-06-11

Study results available
· View outcomes & findings →

Summary

Primary objective of the study was to evaluate the safety and efficacy of canakinumab on the clinical and inflammatory findings of Behced Disease patients with neurologic and vascular involvement.

Conditions

  • Behcet Disease

Interventions

DRUG

Canakinumab

150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)

Sponsors & Collaborators

Principal Investigators

  • Ahmet Gül, Prof · IU Faculty of Medicine

  • Murat Kurtuncu, Ass.Prof · IU Faculty of Medicine

  • Gulsen Akman Demir, Prof · Bilim University Faculty of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-23
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02756650 on ClinicalTrials.gov